UCART22
Phase 2Relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
Data readoutStock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| UCART22 | Relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) | Phase 2 | Dec 31, 2026 | — |
| UCART20x22 | Cancer, Non-Hodgkin lymphoma | Phase 1 | Dec 31, 2026 | — |
Upcoming milestones
Relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
Data readoutCompany profile
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Cancer, Non-Hodgkin lymphoma
Data readout